VAP-1, Eotaxin3 and MIG as potential atherosclerotic triggers of severe calcified and stenotic human aortic valves: Effects of statins

Experimental and Molecular Pathology

Volumn 83, Issue 3, 2007, Pages 435-442

  Anger, Thomas ^a   Pohle, Falk K ^a   Kandler, Lukas ^a   Barthel, Thomas ^a   Ensminger, Stephan M ^a   Fischlein, Theodor ^a   Weyand, Michael ^a   Stumpf, Christian ^a   Daniel, Werner G ^a   Garlichs, Christoph D ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Aortic valve disease; Atherosclerotic inflammation; Gene profiling; Statins

Indexed keywords

ANTIINFLAMMATORY AGENT; CHLORDANE; CXCL9 CHEMOKINE; EOTAXIN; EOTAXIN 3; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULAR ADHESION PROTEIN 1;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; AORTA VALVE STENOSIS; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CAROTID ARTERY; CELL INFILTRATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HEART VALVE REPLACEMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MACROPHAGE; MALE; MICROARRAY ANALYSIS; MONOCYTE; NUCLEOTIDE SEQUENCE; REAL TIME POLYMERASE CHAIN REACTION; SCLEROSIS; STAINING; UPREGULATION;

AMINE OXIDASE (COPPER-CONTAINING); AORTIC VALVE; AORTIC VALVE STENOSIS; ATHEROSCLEROSIS; CALCINOSIS; CELL ADHESION MOLECULES; CHEMOKINE CXCL9; CHEMOKINES, CC; GENE EXPRESSION PROFILING; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MOLECULAR SEQUENCE DATA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TRANSFORMING GROWTH FACTOR BETA;

EID: 36048956919     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2007.02.008     Document Type: Article

References (37)

1. Aikawa M., Rabkin E., Sugiyama S., et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 103 2 (2001) 276-283
2. Bavendiek U., Libby P., Kilbride M., et al. Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor kappa B, and Egr-1. J. Biol. Chem. 277 28 (2002) 25032-25039
3. Bellamy M.F., Pellikka P.A., Klarich K.W., et al. Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. J. Am. Coll. Cardiol. 40 10 (2002) 1723-1730
4. Cowell S.J., Newby D.E., Prescott R.J., et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N. Engl. J. Med. 352 23 (2005) 2389-2397
5. Freeman R.V., and Otto C.M. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation 111 24 (2005) 3316-3326
6. Freeman R.V., Crittenden G., and Otto C. Acquired aortic stenosis. Expert Rev. Cardiovasc. Ther. 2 1 (2004) 107-116
7. Gerdes N., Sukhova G.K., Libby P., et al. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J. Exp. Med. 195 2 (2002) 245-257
8. Ghazvini-Boroujerdi M., Clark J., Narula N., et al. Transcription factor Egr-1 in calcific aortic valve disease. J. Heart Valve Dis. 13 6 (2004) 894-903
9. Haley K.J., Lilly C.M., Yang J.H., et al. Overexpression of Eotaxin and the CCR3 receptor in human atherosclerosis: using genomic technology to identify a potential novel pathway of vascular inflammation. Circulation 102 18 (2000) 2185-2189
10. Jian B., Narula N., Li Q.Y., et al. Progression of aortic valve stenosis: TGF-beta1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis. Ann. Thorac. Surg. 75 2 (2003) 457-465 (discussion 465-6)
11. Kaden J.J., Dempfle C.E., Grobholz R., et al. Interleukin-1 beta promotes matrix metalloproteinase expression and cell proliferation in calcific aortic valve stenosis. Atherosclerosis 170 2 (2003) 205-211
12. Kaden J.J., Bickelhaupt S., Grobholz R., et al. Expression of bone sialoprotein and bone morphogenetic protein-2 in calcific aortic stenosis. J. Heart Valve Dis. 13 4 (2004) 560-566
13. Kaden J.J., Vocke D.C., Fischer C.S., et al. Expression and activity of matrix metalloproteinase-2 in calcific aortic stenosis. Z Kardiol. 93 2 (2004) 124-130
14. Kaden J.J., Dempfle C.E., Grobholz R., et al. Inflammatory regulation of extracellular matrix remodeling in calcific aortic valve stenosis. Cardiovasc. Pathol. 14 2 (2005) 80-87
15. Kawaguchi A., Yutani C., and Yamamoto A. Hypercholesterolemic valvulopathy: an aspect of malignant atherosclerosis. Therap. Apher. Dial. 7 4 (2003) 439-443
16. Kennedy J.H., Henrion D., Wassef M., et al. Osteopontin expression and calcium content in human aortic valves. J. Thorac. Cardiovasc. Surg. 120 2 (2000) 427
17. Kirii H., Niwa T., Yamada Y., et al. Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 23 4 (2003) 656-660
18. Libby P. Inflammation in atherosclerosis. Nature 420 6917 (2002) 868-874
19. Lindroos M., Kupari M., Valvanne J., et al. Factors associated with calcific aortic valve degeneration in the elderly. Eur. Heart J. 15 7 (1994) 865-870
20. Mach F., Sauty A., Iarossi A.S., et al. Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J. Clin. Invest. 104 8 (1999) 1041-1050
21. Muller A.M., Cronen C., Kupferwasser L.I., et al. Expression of endothelial cell adhesion molecules on heart valves: up-regulation in degeneration as well as acute endocarditis. J. Pathol. 191 1 (2000) 54-60
22. Narine K., DeWever O., Cathenis K., et al. Transforming growth factor-beta-induced transition of fibroblasts: a model for myofibroblast procurement in tissue valve engineering. J. Heart Valve Dis. 13 2 (2004) 281-289 (discussion 289)
23. O'Brien K.D., Kuusisto J., Reichenbach D.D., et al. Osteopontin is expressed in human aortic valvular lesions. Circulation 92 8 (1995) 2163-2168
24. Otto C.M. Aortic stenosis and hyperlipidemia: establishing a cause-effect relationship. Am. Heart J. 147 5 (2004) 761-763
25. Otto C.M. Aortic stenosis: even mild disease is significant. Eur. Heart J. 25 3 (2004) 185-187
26. Otto C.M., Burwash I.G., Legget M.E., et al. Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome. Circulation 95 9 (1997) 2262-2270
27. Palta S., Pai A.M., Gill K.S., et al. New insights into the progression of aortic stenosis: implications for secondary prevention. Circulation 101 21 (2000) 2497-2502
28. Pohle K., Otte M., Maffert R., et al. Association of cardiovascular risk factors to aortic valve calcification as quantified by electron beam computed tomography. Mayo Clin. Proc. 79 10 (2004) 1242-1246
29. Rajamannan N.M., Subramaniam M., Springett M., et al. Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation 105 22 (2002) 2660-2665
30. Rajamannan N.M., Subramaniam M., Rickard D., et al. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation 107 17 (2003) 2181-2184
31. Roger V.L., Tajik A.J., Bailey K.R., et al. Progression of aortic stenosis in adults: new appraisal using Doppler echocardiography. Am. Heart J. 119 2 Pt 1 (1990) 331-338
32. Salmi M., Stolen C., Jousilahti P., et al. Insulin-regulated increase of soluble vascular adhesion protein-1 in diabetes. Am. J. Pathol. 161 6 (2002) 2255-2262
33. Satta J., Melkko J., Pollanen R., et al. Progression of human aortic valve stenosis is associated with tenascin-C expression. J. Am. Coll. Cardiol. 39 1 (2002) 96-101
34. Shavelle D.M., Takasu J., Budoff M.J., et al. HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet 359 9312 (2002) 1125-1126
35. Sheikh A.M., Ochi H., Manabe A., et al. Lysophosphatidylcholine posttranscriptionally inhibits interferon-gamma-induced IP-10, Mig and I-Tac expression in endothelial cells. Cardiovasc. Res. 65 1 (2005) 263-271
36. Sukhova G.K., Williams J.K., and Libby P. Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler. Thromb. Vasc. Biol. 22 9 (2002) 1452-1458
37. Yasuda T., Kawasuji M., Sakakibara N., et al. Aortic valve replacement for the calcified ascending aorta in homozygous familial hypercholesterolemia. Eur. J. Cardiothorac. Surg. 18 2 (2000) 249-250